通用名称为REYATAZ
阿扎那韦（硫酸盐）100毫克，150毫克，200毫克，300毫克;上限。
法律分类：
接收
药理班级REYATAZ
HIV - 1蛋白酶抑制剂。
制造商REYATAZ
施贵宝
主治为REYATAZ
HIV - 1感染。
成人剂量为REYATAZ
随身携带的食物。治疗初治：阿扎那韦+利托那韦300毫克100毫克，每日一次，同时，或阿扎那韦400毫克，每日一次，如果无法忍受利托。治疗经验的：阿扎那韦+利托那韦300毫克100毫克;同时每天一次。同时服用依非韦伦（也必须给予利托那韦，用于治疗经验的没有）：阿扎那韦+利托那韦400毫克100毫克（既作为一个单一的每日剂量）+依非韦伦600毫克（在睡前空腹）。伴随泰诺福韦（也必须给予利托那韦）：考虑给予300毫克阿扎那韦+利托那韦+替诺福韦300毫克100毫克，每日剂量为单一所有，见文献。同时服用H2受体阻滞剂或质子泵抑制剂：见文献。终末期肾病血液透析：治疗初治：阿扎那韦+利托那韦300毫克100毫克。中度肝功能不全：300毫克，每日一次。妊娠（第2或第3期）：治疗经验，加上随之而来的H2受体阻滞剂或替诺福韦：atazanvir 400毫克+利托100毫克，均每日一次。所有其他怀孕的患者：无剂量调整需要。产后期：无剂量调整的需要，为在分娩后第2个月不良事件监测。
儿童剂量为REYATAZ
随身携带的食物。 <6yrs：不推荐。 6 - 18yrs：治疗初治：15 - 25KG：阿扎那韦+利托那韦80毫克150毫克; 2532公斤：阿扎那韦+利托那韦200毫克100毫克，3239千克：阿扎那韦+利托那韦250毫克100毫克;≥39千克：阿扎那韦+利托那韦300毫克100毫克;所有：单每日剂量。如果≥13yrs和≥39千克谁是无法容忍利托：阿扎那韦400毫克，每日一次。治疗经验的：<25千克：不推荐。 2532千克：阿扎那韦+利托那韦200毫克100毫克，3239千克：阿扎那韦+利托那韦250毫克100毫克;≥39公斤：阿扎那韦+利托那韦300毫克100毫克，所有的：单日剂量。
禁忌的REYATAZ
由CYP3A或UGT1A1代谢的药物，可能引致严重的事件，如果血液水平升高（例如，阿夫唑嗪，利福平，伊立替康，口服咪达唑仑，三唑仑，ergots，西沙必利，圣约翰草，洛伐他汀，辛伐他汀，匹莫齐特，茚地那韦，西地那非[Revatio治疗，当用于治疗PAH]）。
警告/注意事项为REYATAZ
心脏传导异常。在治疗经验的或严重肝功能不全血液透析的终末期肾病：不推荐。肝损伤。乙型肝炎和/或C：监测肝功能检查。考虑替代抗病毒药物，如果出现黄疸，巩膜黄疸，或乳酸酸中毒发生。糖尿病。监测肾结石，高血糖，脂肪的再分配，以及自发性出血的血友病患者。老人。妊娠（Cat.B）。哺乳母亲：不推荐。
相互作用的REYATAZ
见禁忌。同时服用奈韦拉平，其他蛋白酶抑制剂，沙美特罗或氟替卡松（阿扎那韦+利托那韦）：不推荐。与UGT1A1或CYP3A代谢的药物的注意事项（例如，四咪唑安定，钙通道阻滞剂，他汀类药物，免疫抑制剂，PDE5抑制剂：减少这些剂量治疗ED，在48小时内最高25毫克西地那非，在72小时最大2.5mg伐地那非[阿扎那韦+利托]，最大10毫克他达拉非72小时，他达拉非治疗PAH [见文献]），和CYP2C8（如紫杉醇，瑞格列奈）。 Potentiated由CYP3A抑制剂。拮抗CYP3A诱导剂。谨慎使用和监督地尔硫，抗心律失常药，其他人的影响传导（特别是如果由CYP3A代谢）。考虑减少50％，地尔硫卓或克拉霉素剂量;利福布丁75％的剂量。对克拉霉素变影响;考虑其他药物。血浆水平下降的药物，降低胃液酸度（如H2受体阻滞剂，抗酸剂）。给予12阿扎那韦+利托小时前质子泵抑制剂，避免在治疗中的经验。给予2小时后缓冲或去羟肌苷肠溶之前或1小时。拮抗依非韦伦，波生坦，替诺福韦（见剂量）。增加风险与核苷类似物乳酸性酸中毒。 Potentiates沙奎那韦，曲唑酮，氟替卡松，口服避孕药，酮康唑，伊曲康唑，丁丙诺啡（减少剂量），秋水仙素（特别是肾或肝受损，不要使用）。监测华法林，三环，利福布丁，阿托伐他汀，瑞舒伐他汀，免疫抑制剂。
为REYATAZ不良反应
胃肠不适，胃痛，黄疸，巩膜黄疸，皮疹（可能是严重的，停止，如果发生），头痛，失眠，周围神经病变，眩晕，肌肉痛，抑郁，发热，实验室异常，高血糖，脂肪重新分布，免疫重建综合征，高胆红素血症，肾结石，第二或第三度房室传导阻滞，QT间期延长。儿童：还咳嗽，流鼻涕。
注意事项REYATAZ
注册暴露致电（800）258-4263向阿扎那韦怀孕的患者。参见本节的更多信息Norvir利托条目。
如何REYATAZ提供？
100毫克，150毫克，200毫克，60; 300毫克- 30
REYATAZ
Generic Name for REYATAZ
Atazanavir (as sulfate) 100mg, 150mg, 200mg, 300mg; caps.
Legal Classification:
Rx
Pharmacological Class for REYATAZ
HIV-1 protease inhibitor.
Manufacturer of REYATAZ
Bristol-Myers Squibb
Indications for REYATAZ
HIV-1 infection.
Adult dose for REYATAZ
Take with food. Therapy-naive: atazanavir 300mg + ritonavir 100mg, both once daily; or atazanavir 400mg once daily if unable to tolerate ritonavir. Therapy-experienced: atazanavir 300mg + ritonavir 100mg; both once daily. Concomitant efavirenz (must also give ritonavir; not for therapy-experienced): atazanavir 400mg + ritonavir 100mg (both as a single daily dose) + efavirenz 600mg (on an empty stomach at bedtime). Concomitant tenofovir (must also give ritonavir): consider giving atazanavir 300mg + tenofovir 300mg + ritonavir 100mg; all as a single daily dose; see literature. Concomitant H2 blockers or PPIs: see literature. ESRD with hemodialysis: therapy-naive: atazanavir 300mg + ritonavir 100mg. Moderate hepatic impairment: 300mg once daily. Pregnancy (2nd or 3rd trimester): treatment-experienced plus concomitant H2-blocker or tenofovir: atazanvir 400mg + ritonavir 100mg, both once daily. All other pregnant patients: no dose adjustments needed. Postpartum period: no dose adjustments needed; monitor for adverse events during first 2 months after delivery.
Children's dosing for REYATAZ
Take with food. <6yrs: not recommended. 6–18yrs: Therapy-naive: 15–25kg: atazanavir 150mg + ritonavir 80mg; 25–32kg: atazanavir 200mg + ritonavir 100mg; 32–39kg: atazanavir 250mg + ritonavir 100mg; ≥39kg: atazanavir 300mg + ritonavir 100mg; all: single daily dose. If ≥13yrs and ≥39kg who are unable to tolerate ritonavir: atazanavir 400mg once daily. Therapy-experienced: <25kg: not recommended. 25–32kg: atazanavir 200mg + ritonavir 100mg; 32–39kg: atazanavir 250mg + ritonavir 100mg; ≥39kg: atazanavir 300mg + ritonavir 100mg; all: single daily dose.
Contraindications for REYATAZ
Drugs metabolized by CYP3A or UGT1A1 that may cause serious events if blood levels are elevated (eg, alfuzosin, rifampin, irinotecan, oral midazolam, triazolam, ergots, cisapride, St. John's wort, lovastatin, simvastatin, pimozide, indinavir, sildenafil [Revatio; when used to treat PAH]).
Warnings/Precautions for REYATAZ
Cardiac conduction abnormalities. ESRD with hemodialysis in therapy-experienced or severe hepatic impairment: not recommended. Hepatic impairment. Hepatitis B and/or C: monitor liver function tests. Consider alternative antivirals if jaundice, scleral icterus, or lactic acidosis occurs. Diabetes. Monitor for nephrolithiasis, hyperglycemia, fat redistribution, and hemophiliacs for spontaneous bleeding. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
Interactions for REYATAZ
See Contraindications. Concomitant nevirapine; other protease inhibitors, salmeterol, or fluticasone (atazanavir + ritonavir): not recommended. Caution with drugs metabolized by UGT1A1 or CYP3A (eg, IV midazolam, calcium channel blockers, statins, immunosuppressants, PDE5 inhibitors: reduce doses of these to treat ED; max 25mg sildenafil in 48 hrs; max 2.5mg vardenafil in 72 hrs [atazanavir + ritonavir]; max 10mg tadalafil in 72 hrs; tadalafil to treat PAH [see literature]), and CYP2C8 (eg, paclitaxel, repaglinide). Potentiated by CYP3A inhibitors. Antagonized by CYP3A inducers. Use cautiously and monitor diltiazem, antiarrhythmics, others that affect conduction (esp. if metabolized by CYP3A). Consider reducing diltiazem or clarithromycin dose by 50%; rifabutin dose by 75%. Variable effects on clarithromycin; consider other drugs. Plasma levels decreased by drugs that reduce gastric acidity (eg, H2 blockers, antacids). Give proton pump inhibitors 12 hours before atazanavir + ritonavir; avoid in therapy-experienced. Give 2 hours before or 1 hour after buffered or enteric coated didanosine. Antagonized by efavirenz, bosentan, tenofovir (see dose). Increased risk of lactic acidosis with nucleoside analogues. Potentiates saquinavir, trazodone, fluticasone, oral contraceptives, ketoconazole, itraconazole, buprenorphine (reduce dose), colchicine (esp. renal or hepatic impaired; do not use). Monitor warfarin, tricyclics, rifabutin, atorvastatin, rosuvastatin, immunosuppressants.
Adverse Reactions for REYATAZ
GI upset, stomach pain, jaundice, scleral icterus, rash (may be severe; discontinue if occurs), headache, insomnia, peripheral neuropathy, dizziness, myalgia, depression, fever, lab abnormalities, hyperglycemia, fat redistribution, immune reconstitution syndrome, hyperbilirubinemia, nephrolithiasis, 2nd or 3rd-degree AV block, QT prolongation. Children: also cough, rhinorrhea.
Notes for REYATAZ
Register pregnant patients exposed to atazanavir by calling (800) 258-4263. See Norvir entry in this section for more information on ritonavir.
How is REYATAZ supplied?
100mg, 150mg, 200mg—60; 300mg—30